HER2 Pos MBC Tx Seq

CE / CME

HER2+ Metastatic Breast Cancer: Expert Perspectives on Sequencing of Therapy and Navigating Brain Metastases

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: May 12, 2025

Expiration: November 11, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

When discussing treatment plans with colleagues and patients, how confident are you in summarizing the recommended sequencing of HER2-targeted therapies for HER2-positive MBC treatment based on the latest data and clinical guidelines?

2.

Which of the following were key findings of the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine (T-DM1) vs T-DM1 plus placebo for the treatment of previously treated HER2-positive MBC?

3.

Mary, a 57-year-old patient, is diagnosed with metastatic hormone receptor–negative/HER2-positive breast cancer with 1 small liver lesion. Twenty-four months after taxane with trastuzumab and pertuzumab (THP) treatment, she progresses on maintenance trastuzumab and pertuzumab (HP) with disease progression in the liver and develops 1 brain lesion. She then received trastuzumab deruxtecan (T-DXd) and had a partial response, but 8 months later, she has developed new liver metastases and MRI shows 3 new brain lesions.

After local therapy to the brain, which of these regimens would you recommend for Mary now?